UCM-1306

UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM) . UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) [1].

Product Specifications

CAS Number

[2258608-78-3]

UNSPSC

12352005

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ucm-1306.html

Purity

99.61

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(C2=C(OCF)C=CC=C2)C=C1)(C)=N

Molecular Formula

C14H14FNO2S

Molecular Weight

279.33

References & Citations

[1]García-Cárceles J, et, al. 2- (Fluoromethoxy) -4'- (S-methanesulfonimidoyl) -1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease. J Med Chem. 2022 Sep 22;65 (18) :12256-12272.